Carbidopa-Levodopa in Dry AMD With Geographic Atrophy
Status:
Active, not recruiting
Trial end date:
2021-03-01
Target enrollment:
Participant gender:
Summary
From 3 large patient databases, patients diagnosed with AMD who have never taken
levodopa(L-DOPA) containing medications have a mean age of diagnosis at 71 years.
Patients who have been treated with L-DOPA containing medications have a mean age of
diagnosis of AMD at 79 years. L-DOPA binds to GPR143 in the retinal pigment epithelium, and
releases PEDF, which protects the retina and downregulates VEGF, which is the cause of
neovascularization.
The Investigators will evaluate the safety and tolerability of carbidopa-levodopa in patients
with Neovascular AMD, and measure the effects on visual acuity and retinal abnormalities due
to "wet" (neovascular) AMD. The Investigators will evaluate the safety and tolerability of
carbidopa-levodopa in patients with Dry AMD and Geographic Atrophy, and measure the effects
on visual acuity, area of geographic atrophy and other retinal abnormalities due to "dry"
AMD.
Phase:
Phase 2
Details
Lead Sponsor:
Snyder, Robert W., M.D., Ph.D., P.C.
Treatments:
Carbidopa Carbidopa, levodopa drug combination Levodopa